Dose escalation with repeated intrathecal injections of 131I-labelled MAbs for the treatment of central nervous system malignancies.

We have previously demonstrated a 33% response rate in patients with primitive neurectodermal tumours after the direct injection of 131I-monoclonal antibodies (MAbs) into the cerebrospinal fluid (CSF). Dose-limiting toxicity is myelosuppression due to the passage of the radioimmunoconjugate from the...

Descripción completa

Detalles Bibliográficos
Autores principales: Kemshead, J. T., Hopkins, K., Pizer, B., Papanastassiou, V., Coakham, H., Bullimore, J., Chandler, C.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1998
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150406/
https://www.ncbi.nlm.nih.gov/pubmed/9649153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150406/
https://www.ncbi.nlm.nih.gov/pubmed/9649153

Ejemplares similares